Early portopulmonary hypertension predicts mortality in patients with cirrhosis: Insights from the PORTO-DETECT cohort


Por: Téllez, L, Donate, J, Guerrero, A, Beraza, IA, San Martín, D, Alvarado, E, Echevarria, V, Puente, A, Zamora, J, Del Prado, S, Tenes, A, Balagué, G, Vidal, B, Geli, C, Rodriguez-Gandia, MA, Baiges, A, Brujats, A, Rodríguez, DLH, Sánchez, SFG, Fortea, JI, del Cerro, MJ, Villanueva, C, Garcia-Pagán, JC, Giráldez, A, Albillos, A

Publicada: 1 feb 2026 Ahead of Print: 1 ene 2026
Resumen:
Background & Aims: Portopulmonary hypertension (PoPH) is a severe complication of cirrhosis and portal hypertension. In 2022, a European task force revised the diagnostic criteria for pulmonary arterial hypertension (PAH), defining early stages as a mean pulmonary arterial pressure (mPAP) of 20.5-24.5 mmHg and pulmonary vascular resistance (PVR) >2 Wood units. We evaluated the prognostic value of these revised criteria in patients with cirrhosis. Methods: In this longitudinal, multicenter, observational cohort, 428 adults with cirrhosis and portal hypertension underwent right-heart catheterization between 2015 and 2023 and were stratified into five groups: normal, early PoPH, classic PoPH, post-capillary pulmonary hypertension, and unclassified profiles. All-cause mortality was analyzed by multivariable Cox regression and competing-risk models, with liver transplantation as an intercurrent event. Results: Over a median follow-up time of 20.0 months (IQR 8.0-36.0), 3-year survival rates were 76.7%, 49.5%, and 42.0% in the normal mPAP, early PoPH, and classic PoPH groups, respectively. After adjustment for age, sex, liver function, and portal hypertension severity, both early PoPH (hazard ratio 3.5; 95% CI 1.9-6.3; p <0.01) and classic PoPH (hazard ratio 4.5; 2.6-7.6; p <0.01) remained independent predictors of mortality vs. normal mPAP; these associations persisted in competing-risk analysis, whereas post-capillary pulmonary hypertension and unclassified groups did not differ from the normal mPAP cohort. Conclusion: Applying the 2022 ESC/ERC definitions of PAH identifies a subset of patients with cirrhosis with early-stage PoPH, characterized by mild pulmonary vascular resistance elevation, who nevertheless face a markedly increased risk of death, emphasizing the need for systematic screening and early targeted intervention. (c) 2025 European Association for the Study of the Liver. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

Filiaciones:
Téllez, L:
 Univ Alcala, Hosp Univ Ramon Y Cajal, Gastroenterol & Hepatol Dept, IRYCIS,CIBERehd, Ctra Colmenar Viejo,Km 9 100, Madrid 28034, Spain

Donate, J:
 Univ Alcala, Hosp Univ Ramon Y Cajal, Gastroenterol & Hepatol Dept, IRYCIS,CIBERehd, Ctra Colmenar Viejo,Km 9 100, Madrid 28034, Spain

Guerrero, A:
 Univ Alcala, Hosp Univ Ramon Y Cajal, Gastroenterol & Hepatol Dept, IRYCIS,CIBERehd, Ctra Colmenar Viejo,Km 9 100, Madrid 28034, Spain

Beraza, IA:
 Univ Seville, Hosp Univ Virgen Rocio, Digest Dis Dept, Inst Biomed,HUVR,CSIC,US, Seville, Spain

San Martín, D:
 Inst Invest Biomed August Pi I Sunyer IDIBAPS, Ctr Invest Biomed Red Enfermedades Hepat & Digest, Barcelona Hepat Hemodynam Lab, Liver Unit,Hosp Clin, Barcelona, Spain

 Univ Barcelona, Dept Med & Ciencies Salut, European Reference Network Rare Liver Disorders ER, Barcelona, Spain

Alvarado, E:
 Hosp Santa Creu & Sant Pau, Dept Gastroenterol, Barcelona, Spain

 Autonomous Univ Barcelona UAB, Biomed Res Inst St Pau IIB St Pau, Dept Med, Barcelona, Spain

 Inst Salud Carlos III, Digest Dis Network CIBERehd, Ctr Biomed Res Liver, Madrid, Spain

Echevarria, V:
 Marques Valdecilla Univ Hosp, Valdecilla Res Inst IDIVAL, Gastroenterol & Hepatol Dept, Clin & Translat Res Digest Dis, Santander, Spain

Puente, A:
 Marques Valdecilla Univ Hosp, Valdecilla Res Inst IDIVAL, Gastroenterol & Hepatol Dept, Clin & Translat Res Digest Dis, Santander, Spain

Zamora, J:
 Hosp Univ Ramon y Cajal IRYCIS, Clin Biostat Unit, Madrid, Spain

 CIBER Epidemiol & Publ Hlth CIBERES, Madrid, Spain

 Univ Birmingham, WHO Collaborating Ctr Global Womenns Hlth, Inst Metab & Syst Res, Birmingham, England

Tenes, A:
 Univ Alcala, Hosp Univ Ramon Y Cajal, Resp Dis Dept, IRYCIS, Madrid, Spain

Balagué, G:
 Univ Barcelona, Hosp Clin, Cardiovasc Inst, Dept Cardiol, Barcelona, Spain

Vidal, B:
 Univ Barcelona, Hosp Clin, Cardiovasc Inst, Dept Cardiol, Barcelona, Spain

Geli, C:
 Hosp Santa Creu & Sant Pau, Dept Gastroenterol, Barcelona, Spain

 Autonomous Univ Barcelona UAB, Biomed Res Inst St Pau IIB St Pau, Dept Med, Barcelona, Spain

 Inst Salud Carlos III, Digest Dis Network CIBERehd, Ctr Biomed Res Liver, Madrid, Spain

Rodriguez-Gandia, MA:
 Univ Alcala, Hosp Univ Ramon Y Cajal, Gastroenterol & Hepatol Dept, IRYCIS,CIBERehd, Ctra Colmenar Viejo,Km 9 100, Madrid 28034, Spain

Baiges, A:
 Inst Invest Biomed August Pi I Sunyer IDIBAPS, Ctr Invest Biomed Red Enfermedades Hepat & Digest, Barcelona Hepat Hemodynam Lab, Liver Unit,Hosp Clin, Barcelona, Spain

 Univ Barcelona, Dept Med & Ciencies Salut, European Reference Network Rare Liver Disorders ER, Barcelona, Spain

Brujats, A:
 Inst Invest Biomed August Pi I Sunyer IDIBAPS, Ctr Invest Biomed Red Enfermedades Hepat & Digest, Barcelona Hepat Hemodynam Lab, Liver Unit,Hosp Clin, Barcelona, Spain

 Univ Barcelona, Dept Med & Ciencies Salut, European Reference Network Rare Liver Disorders ER, Barcelona, Spain

Rodríguez, DLH:
 Hosp Univ Virgen Rocio, Anesthesiol Dept, Seville, Spain

Sánchez, SFG:
 Hosp Univ Virgen Rocio, Cardiol Dept, Seville, Spain

Fortea, JI:
 Marques Valdecilla Univ Hosp, Valdecilla Res Inst IDIVAL, Gastroenterol & Hepatol Dept, Clin & Translat Res Digest Dis, Santander, Spain

del Cerro, MJ:
 Univ Alcala, Pediat Cardiol & Cardiac Congenital Dis Dept, IRYCIS, Madrid, Spain

Villanueva, C:
 Inst Invest Biomed August Pi I Sunyer IDIBAPS, Ctr Invest Biomed Red Enfermedades Hepat & Digest, Barcelona Hepat Hemodynam Lab, Liver Unit,Hosp Clin, Barcelona, Spain

 Univ Barcelona, Dept Med & Ciencies Salut, European Reference Network Rare Liver Disorders ER, Barcelona, Spain

Garcia-Pagán, JC:
 Inst Invest Biomed August Pi I Sunyer IDIBAPS, Ctr Invest Biomed Red Enfermedades Hepat & Digest, Barcelona Hepat Hemodynam Lab, Liver Unit,Hosp Clin, Barcelona, Spain

 Univ Barcelona, Dept Med & Ciencies Salut, European Reference Network Rare Liver Disorders ER, Barcelona, Spain

Giráldez, A:
 Univ Seville, Hosp Univ Virgen Rocio, Digest Dis Dept, Inst Biomed,HUVR,CSIC,US, Seville, Spain

Albillos, A:
 Univ Alcala, Hosp Univ Ramon Y Cajal, Gastroenterol & Hepatol Dept, IRYCIS,CIBERehd, Ctra Colmenar Viejo,Km 9 100, Madrid 28034, Spain

Hosp Univ Ramon Y Cajal, Univ Alcala, Cardiol Dept, IRYCIS,CIBERCV, Madrid, Spain
ISSN: 01688278





JOURNAL OF HEPATOLOGY
Editorial
ELSEVIER, RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS, Países Bajos
Tipo de documento: Article
Volumen: 84 Número: 2
Páginas:
WOS Id: 001673830000001
ID de PubMed: 41076090
imagen Green Accepted

MÉTRICAS